AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
| MTHRY Stock | USD 4.60 0.02 0.43% |
Slightly above 62% of M3's investor base is looking to short. The analysis of overall sentiment of trading M3 Inc pink sheet suggests that many investors are alarmed at this time. M3's investing sentiment can be driven by a variety of factors including economic data, M3's earnings reports, geopolitical events, and overall market trends.
M3 |
Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Read at zacks.com
 |
M3 Fundamental Analysis
We analyze M3's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of M3 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of M3 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
M3 is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
M3 Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with M3 pink sheet to make a market-neutral strategy. Peer analysis of M3 could also be used in its relative valuation, which is a method of valuing M3 by comparing valuation metrics with similar companies.
Peers
M3 Related Equities
| HCAT | Health Catalyst | 6.14 | ||||
| CERT | Certara | 6.04 | ||||
| DH | Definitive Healthcare | 2.82 | ||||
| PRVA | Privia Health | 2.28 | ||||
| TDOC | Teladoc | 2.12 | ||||
| HSTM | HealthStream | 1.16 | ||||
| AMWL | American Well | 1.12 | ||||
| DOCS | Doximity | 0.42 | ||||
| HQY | HealthEquity | 0.38 | ||||
| NRC | National Research | 1.75 |
Additional Tools for M3 Pink Sheet Analysis
When running M3's price analysis, check to measure M3's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy M3 is operating at the current time. Most of M3's value examination focuses on studying past and present price action to predict the probability of M3's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move M3's price. Additionally, you may evaluate how the addition of M3 to your portfolios can decrease your overall portfolio volatility.